Skip to main content

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

Terminated · Phase 2 · NCT04698187

Conditions: Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma

At a glance

Research payments reported, 2025
$293,891
U.S. investigators named
2
Sites paid
2
Planned or actual enrollment
44

About the trial

Sponsor
Regeneron Pharmaceuticals (with Bristol-Myers Squibb)
Tested
CMP-001 (drug), Nivolumab (drug)
Dates
Started 2021-03-11; completion 2024-02-05
Results posted
Yes

CMP-001-010 is a Phase 2 study of CMP-001 intratumoral (IT) and nivolumab intravenous (IV) administered to participants with refractory unresectable or metastatic melanoma. The primary objective of the study is to determine confirmed objective response with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma. The secondary objectives are to: * To evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma. * To evaluate the efficacy of CMP-001 in combination with nivolumab in subjects with refractory unresectable or…

From ClinicalTrials.gov, last updated 2025-06-11. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Regeneron Pharmaceuticals, Inc. reported $293,891 in research payments for this study in 2025 (32 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.